P. Jordan

发表

Modelling of mortality data from a multi-centre study in Japan by means of Poisson regression with error in variables.

S. Tsugane, Y. Tsubono, Y Tsubono, 1997, International journal of epidemiology.

Increased risk of cardiovascular disease at suboptimal plasma concentrations of essential antioxidants: an epidemiological update with special attention to carotene and vitamin C.

H. Stähelin, M. Eichholzer, K. Gey, 1993, The American journal of clinical nutrition.

Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology.

P. Puska, K. Gey, U. Moser, 1991, The American journal of clinical nutrition.

Subcutaneous injection pain with C.E.R.A., a continuous erythropoietin receptor activator, compared with darbepoetin alfa

F. C. Dougherty, B. Reigner, P. Jordan, 2007, Current medical research and opinion.

No Evidence of QT Prolongation With Supratherapeutic Doses of Aleglitazar

D. Bentley, P. Jordan, S. Sturm, 2012, Journal of cardiovascular pharmacology.

Pharmacokinetic and Pharmacodynamic Properties of Methoxy Polyethylene Glycol‐Epoetin Beta Are Unaffected by the Site of Subcutaneous Administration 1

F. C. Dougherty, B. Reigner, S. Fishbane, 2007 .

Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial.

N. Stefan, J. Machann, M. Roden, 2014, The lancet. Diabetes & endocrinology.

A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier

T. Bergauer, O. Khwaja, K. Heinig, 2018, British journal of clinical pharmacology.

Effect of hemodialysis and hemofiltration on plasma C.E.R.A. concentrations

B. Reigner, J. Leypoldt, P. Jordan, 2011, Hemodialysis international. International Symposium on Home Hemodialysis.

Thorough QT/QTc Study of Ritonavir‐Boosted Saquinavir Following Multiple‐Dose Administration of Therapeutic and Supratherapeutic Doses in Healthy Participants

Xiaoping Zhang, S. Kolis, P. Jordan, 2012, Journal of clinical pharmacology.

Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease.

F. C. Dougherty, B. Reigner, I. Macdougall, 2006, Clinical journal of the American Society of Nephrology : CJASN.

The effect of severe hepatic impairment on the pharmacokinetics and haematological response of C.E.R.A.

F. C. Dougherty, B. Reigner, V. Kupčová, 2008, Current medical research and opinion.

Vitamin C concentrations in plasma as a function of intake: a meta-analysis.

U. Moser, P. Jordan, D. Brubacher, 2000, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition.

Vitamin E and vitamin A concentrations in plasma adjusted for cholesterol and triglycerides by multiple regression.

H. Stähelin, K. Gey, U. Moser, 1995, Clinical chemistry.

Depletion of plasma vitamin C but not of vitamin E in response to cardiac operations.

P. Ballmer, W. Reinhart, K. Gey, 1994, The Journal of thoracic and cardiovascular surgery.

A Phase I Study to Assess the Effect of Speed of Injection on Pain, Tolerability, and Pharmacokinetics After High-volume Subcutaneous Administration of Gantenerumab in Healthy Volunteers.

C. Hofmann, Thijs MP van Iersel, P. Jordan, 2019, Clinical therapeutics.

Phase I clinical study to select a novel oral formulation for ibandronate containing the excipient sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC).

N. Fotaki, N. Shah, H. Chokshi, 2012, Die Pharmazie.

賦形剤N-[8-(2-ヒドロキシベンゾイル)アミノ]カプリル酸ナトリウム含有イバンドロナートについて新規経口製剤選択のための第I相臨床試験

N. Fotaki, N. Shah, H. Chokshi, 2012 .

Explicit solutions for a class of indirect pharmacodynamic response models

P. Jordan, R. Gieschke, R. Gieschke, 2005, Comput. Methods Programs Biomed..

Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administration.

F. C. Dougherty, B. Reigner, S. Fishbane, 2007, Journal of clinical pharmacology.

A comparison of the theoretical relationship between HDL size and the ratio of HDL cholesterol to apolipoprotein A-I with experimental results from the Women's Health Study.

Samia Mora, Nina P Paynter, Franco Giulianini, 2013, Clinical chemistry.

Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of 5-HT1A Receptor Agonists: Estimation of in Vivo Affinity and Intrinsic Efficacy on Body Temperature in Rats

L. Peletier, M. Danhof, P. H. van der Graaf, 2004, Journal of Pharmacology and Experimental Therapeutics.

Bayesian adaptive designs in single ascending dose trials in healthy volunteers.

Ulrich Beyer, Nicolas Frey, Bruno Reigner, 2014, British journal of clinical pharmacology.

Aleglitazar, a balanced PPARα/γ agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin

Anne-Marie Young, P. Jordan, Fiona Russell-Yarde, 2011, Expert opinion on investigational drugs.

Drug-drug interaction study between a novel oral ibandronate formulation and metformin

P. Jordan, B. Bittner, Johannes Schmidt, 2011, Arzneimittelforschung.

Oral administration of the 11β-hydroxysteroid-dehydrogenase type 1 inhibitor RO5093151 to patients with glaucoma: an adaptive, randomised, placebo-controlled clinical study

D. Hainzl, W. C. Stewart, D. Schwab, 2017, BMJ Open Ophthalmology.

Estimation of tolerance limits from reference data

P. Jordan, 1995 .

Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial.

N. Stefan, J. Machann, M. Roden, 2014, The lancet. Diabetes & endocrinology.

Sequentially updating the likelihood of success of a Phase 3 pivotal time-to-event trial based on interim analyses or external information

Markus Abt, Kaspar Rufibach, Paul Jordan, 2016, Journal of biopharmaceutical statistics.